The challenge of developing robust drugs to overcome resistance

Amy C. Anderson, University of Connecticut
Michael P. Pollastri, Northeastern University
Celia A. Schiffer, University of Massachusetts Medical School
Norton P. Peet, Microbiotix, Inc.

Abstract

Drug resistance is problematic in microbial disease, viral disease and cancer. Understanding at the outset that resistance will impact the effectiveness of any new drug that is developed for these disease categories is imperative. In this Feature, we detail approaches that have been taken with selected drug targets to reduce the susceptibility of new drugs to resistance mechanisms. We will also define the concepts of robust drugs and resilient targets, and discuss how the design of robust drugs and the selection of resilient targets can lead to successful strategies for combating resistance.